Search

A newly approved imaging technology can identify the location of prostate cancer cells, allowing doctors to choose the best treatment.

Metastasis is responsible for about 9 of every 10 cancer deaths, and it remains one of the most daunting and least understood aspects of the disease. Researchers across MSK are approaching a wide variety of metastatic cancer types from many directions.

For more than a decade, Memorial Sloan Kettering Cancer Center’s (MSK) Visible Ink writing program has given a voice to more than 3,000 people with cancer, allowing each of them a unique opportunity to express themselves through interpretive dance, music, and poetry.

Therapies that target genetic alterations in tumors are showing promise for many cancer patients, but challenges in developing these new treatments remain.

Find tools for discussing a cancer diagnosis with your children.

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the best cancer center in the northeast, the number two hospital for cancer care in the nation, and the number one hospital nationally for urology care by U.S. News & World Report in its annual Best Hospitals listing.

Scientists at the Sloan Kettering Institute have discovered that the ability of cancers to metastasize to other organs is dependent upon their ability to co-opt natural wound-healing pathways. In a literal sense, metastasis is wound healing gone wrong. These findings provide a novel framework for thinking about metastasis and how to treat it.

Jae Park, MD, a hematologic oncologist and assistant attending physician at MSK, will present findings about the durability of CAR T cell therapy response in patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) at the American Association for Cancer Research (AACR) Annual Meeting. This research has been selected to be featured in the meeting’s press program.